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Objective: To study the effects of inhibited Annexin A2 (ANXA2) on human umbilical
vein endothelial cells (HUVECs) in vitro.
Methods: Short hairpin RNA (shRNA) targeting ANXA2 was designed and cloned into
double marked lentivirial vector GV248 for RNAi to generate the recombinant expression
plasmids, which were stably transfected into HUVECs. The protein and mRNA
expression levels of ANXA2 were analyzed by western blotting and real-time polymerase
chain reaction, respectively. Cell proliferation (cell counting kit-8 assay), apoptosis (ﬂow
cytometry analysis), the expression (western blotting) and the activity of caspases
(enzyme-linked immunosorbent assay) were used to assess the effects of silencing
ANXA2 on HUVECs in vitro.
Results: The plasmids to express ANXA2-speciﬁc shRNA were constructed and were
infected into HUVEC resulting in the stably transfected experimental (ANXA2-shRNA),
control (control-shRNA) and mock (no plasmid) cell lines, which were veriﬁed with
western blot and real-time PCR. HUVEC/ANXA2-shRNA showed an inhibition rate
91.89% of ANXA2 expression compared to the mock HUVEC. ANXA2 silencing cell
strain obviously presented a lower cell proliferation activity compared to the control and
mock HUVECs, with an inhibition rate 82.35% on day 7 in vitro. FACS analysis indi-
cated that the HUVEC/ANXA2-shRNA cells undergoing apoptosis increased by
102.61% compared to the mock HUVECs (P < 0.01). Moreover, the activity levels of
caspase-3, caspase-8 and caspase-9 in HUVEC/ANXA2-shRNA cells were increased and
the activated cleaved caspase-3, cleaved caspase-8 and cleaved caspase-9 were upregu-
lated evidently compared with that of the control and mock HUVECs by 56.29%, 89.59%
and 144.58% (P < 0.01).
Conclusions: shRNA-mediated silencing of ANXA2 could not only be able to suppress
HUVECs proliferation but to upregulate the enzyme activity of caspases, which bring to
an increase of cell apoptosis. This work suggested that ANXA2 may represent a useful
target of future molecular therapies.1. Introduction
Annexin A2 (ANXA2), a kind of calcium depended mem-
brane phospholipids binding protein, is one of the important
members of Annexins family which widely expressed in cell
membrane, cytoplasm and extracellular matrix [1,2]. ANXA2 canfunction in many life activities, such as formation of cell
membrane structure, membrane fusion, signal transduction,
cell migration, DNA synthesis, cell proliferation and cell
apoptosis. It is also reported that ANXA2 may play a key role
in the retinal neovascularization. With its partner S100A10
(p11), ANXA2 is able to form a heterotetrameric complex [3–
10], which binds both plasminogen and its activator (tissue
plasminogen activator, tPA) to accelerate the generation of
plasmin [11–17]. The isolated endothelial cells from the mice
deﬁcient in annexin A2 (ANXA2−/−) are unable to support
tPA-dependent plasminogen activation in vitro [18,19] and the
ANXA2−/− mice exhibit reduced angiogenesis in growth
factor-stimulated assays in adulthood. Retinal neo-
vascularization is a common pathological change of many eyeaccess article under the CC BY-NC-ND
Shu-Le Jiang et al./Asian Paciﬁc Journal of Tropical Medicine 2015; 8(11): 952–957 953diseases, which results in wide injury to eyes to get blindness
[20]. We assumed that ANXA2 may affect the process of
neovascularization of the retina, so the objectives of the
present study were to focus on the effects of silencing
ANXA2 by small hairpin RNA (shRNA) on human umbilical
vein endothelial cells (HUVECs) in vitro that is usually used
in the study of angiogenesis. We found that shRNA-mediated
silencing of ANXA2 could not only be able to suppress
HUVECs proliferation but to upregulate the enzyme activity of
caspases, which bring to an increase of cell apoptosis.
2. Materials and methods
2.1. Plasmid construction
The shDNAs encoding ANXA2-speciﬁc shRNA targeting
ANXA2 nucleotides (GeneBank: NM_001002858) (Table 1),
which were designed with the free software OPtiRNA (http://
optirna.unl.edu/) and synthesized as by GeneChem, China, were
used to construct experimental plasmids (pGV248/ANXA2-
shRNA) by inserting into an Age I and EcoR I linearized
pGV248, an shRNA shuttle expression vector containing a green
ﬂuorescent protein reporter gene (GeneChem, China). A negative
control vector (pGV248/control-shRNA) was constructed simi-
larly with an unrelated shRNA sequence that does not suppress
the expression of genes expressed in humans (GeneChem). All
inserted sequences were veriﬁed by DNA sequencing.
2.2. Cell culture
HUVEC cells were obtained from ATCC, USA. The cells
were cultured in Ham's-F12K medium (Zhongqiaxinzhou Bio-
technologies, China), supplemented with 5% fetal calf serum,
100 U/mL penicillin, and 0.1 mg/mL streptomycin in a hu-
midiﬁed atmosphere with 5% CO2 at 37 C.
2.3. Cell transfection
For experimentation, HUVEC cells were in vitro seeded into
24-well plates, allowed to grow to 80%–90% conﬂuence, and
transfected by plasmids (pGV248/control-shRNA and pGV248/
ANXA2-shRNA) with DNA Transfection Reagent (Invitrogen,
USA) according to the manufacturer's instruction. At 48 h after
transfection, cells were selected by culturing in the presence of
400 mg/mL of G418 (Sangon Biotech, China) for 2 weeks. In-
dividual G418-resistant monoclonals were obtained by per-
forming a limiting dilution with subsequent proliferation in
medium supplemented with 200 mg/mL of G418 to generate the
stably transfected experimental (HUVEC/ANXA2-shRNA),
control (HUVEC/control-shRNA) and mock (no plasmid) cell
lines. The efﬁciency of infection was monitored by ﬂuorescence
microscopy.Table 1
Synthesized shDNAs encoding ANXA2-speciﬁc shRNA.
ID 50 Stem
ANXA2 ccgg CGGGATGCTTTGAACATTGAA
aattcaaaaa CGGGATGCTTTGAACATTGAA
Control ccgg CTACCGTTGTTAAGGTGT
aattcaaaaa CTACCGTTGTTAAGGTGT2.4. Real-time PCR analysis
Total RNA was isolated from cells using an RNeasy kit
(Invitrogen, USA). Single-stranded cDNA was synthesized from
1 mg total RNA using an oligo (dT) 18-mer as primer, and
reverse transcription (Invitrogen, USA) in a ﬁnal reaction vol-
ume of 25 mL. Quantitative real-time PCR was performed using
the TaqMan method and Probe Real Master Mix (Tiangen
Biotech, Beijing, China) in a 7 500 real-time PCR System
(Applied Biosystems Inc, CA). GAPDH was used as control.
The following primers were used: i) ANXA2 forward, 50-
GTGAAGAGGAAAGGAACCGA-30 and reverse, 50-
CTTGATGCTCTCCAGCATGT-3'; and ii) GAPDH forward,
50-GCCTTCCGTGTTCCTACC-30 and reverse, 50-
AGAGTGGGAGTTGCTGTTG-3'. The analysis was performed
using the 2−DDCt method and the relative value of ANXA2
mRNA expression was normalized to GAPDH gene expression.
2.5. Western blot analysis
Total protein was isolated from cultured cells with the use of
an extraction kit (Sangon Biotech, China) according to the
manufacturer's instructions. Each 20 mg of protein was sepa-
rated by 15% SDS-PAGE and then transferred onto PVDF
membranes and blocked with 3% BSA in Tris-buffer. Mouse
anti-human monoclonal antibody (Cell Signaling Technology,
USA) was used. Detection was performed with HRP-conjugated
goat anti-mouse immunoglobulins and enhanced chem-
iluminescence (Clinx, China). Bands were subsequently visual-
ised and analyzed by a ChemiScope5600 integrated
chemiluminescence imaging system (Clinx, China). ANXA2
levels were presented as relative ratio (RR) and calculated using
the formula for signal intensity (SI) of ANXA2 and GAPDH:
RR = SIANXA2/SIGAPDH.
2.6. Cell proliferation assay
Cell proliferation was evaluated using a cell counting kit-8
(Beyotime Institute of Biotechnology, China). Cells and blank
controls were seeded in 96-well plates (2 × 103 cells/well with
100 mL medium) and for 24 h. Next, 10 mL CCK-8 solution was
added to the culture medium for 2 h and the absorbance (A490)
was recorded by a microplate reader (BioTek, USA). This was
repeated 3 times at various time points.
2.7. Enzyme-linked immunosorbent assay
HUVEC caspase-8, caspase-9 and caspase-3 levels were
estimated with the use of enzyme-linked immunosorbent assay
kits (Innovative Research, USA) according to the manufacturer's
instructions. Colorimetric analysis was performed on a micro-
plate reader (Bio-Rad Laboratories, USA) and the absorbanceLoop Stem 30
CTCGAG TTCAATGTTCAAAGCATCCCG TTTTTg
CTCGAG TTCAATGTTCAAAGCATCCCG
CTCGAG GACACCTATAACAACGGTAG TTTTTg
CTCGAG GACACCTATAACAACGGTAG
Figure 2. Real-time PCR of ANXA2 in HUVECs with siANXA2 trans-
fection immediately.
M, mock HUVEC; C, HUVEC/control-shRNA; A, HUVEC/ANXA2-
shRNA.
Figure 3. Cell proliferation assay.
*P < 0.05, **P < 0.01 vs. mock HUVEC. M, mock HUVEC; C, HUVEC/
control-shRNA; A, HUVEC/ANXA2-shRNA.
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concentrations according to the standard curve generated.
2.8. FCM analysis of cell apoptosis
HUVEC/ANXA2-shRNA, HUVEC/control-shRNA and the
mock HUVECs were stained relatively with FITC-conjugated
annexin V and propidium iodide (PI) as supplied by an
apoptosis detection kit (Beyotime, China). Cells were analyzed
using a FACSCalibur (BD Biosciences, USA).
2.9. Statistical analysis
Statistical signiﬁcance was assessed by the 2-tailed Student t
test. P values of <0.05 were considered statistically different.
3. Results
3.1. ANXA2 expression in HUVEC cells is inhibited by
shRNA in vitro
The silencing efﬁciency of ANXA2-speciﬁc shRNA in
HUVEC cells reached approximately 82%. As shown in
Figure 1b, the ratio of ANXA2 to GAPDH demonstrated that the
expression levels of ANXA2 protein were signiﬁcantly lower in
the HUVEC/ANXA2-shRNA cells than in the HUVEC/control-
shRNA cells and in the mock HUVECs (P < 0.01). The levels
detected in the HUVEC/control-shRNA cells and HUVECs
were not signiﬁcantly different (P > 0.05). It was suggested that
the ANXA2 mRNA was markedly downregulated following
transfection with stably expressing shRNA at the protein level.
3.2. ANXA2 mRNA expression after RNA interference
in vitro
Quantitative PCR showed that the expression of ANXA2
mRNA in HUVECs transfected with shANXA2 was signiﬁ-
cantly inhibited (Figure 2), and the reduction of the ANXA2
mRNA expressions was 85% down (P < 0.01). The mRNA
relative levels were measured in sample rate/cutoff rate (S/CO).Figure 1. ANXA2 expression level in HUVECs and silencing efﬁciency of sh
(a): Representative immunoﬂuorescence images. (b): Representative Western blo
mock HUVEC. M, mock HUVEC; C, HUVEC-control-shRNA; A, HUVEC-A3.3. Suppression of HUVEC proliferation
The effect of ANXA2 suppression on the proliferation
following transfection with speciﬁc shRNA is shown in
Figure 3. At 72 h after transfection, the cell proliferation abilityRNA.
tting image of ANXA2 silencing upon transfection of shRNA. *P < 0.01 vs.
NXA2-shRNA.
Figure 4. FACS analysis of HUVEC apoptosis.
M, mock HUVEC; C, HUVEC/control-shRNA; A, HUVEC/ANXA2-shRNA. Right lower quadrant: early apoptotic cells; Left upper quadrant: dead cells;
Left lower quadrant: live cells; Right upper quadrant: late apoptotic cells. All apoptosis experiments were carried out more than twice. Results were similar
and one representative experiment is shown.
Table 2
Activity levels of caspase-3, -8 and -9 in HUVECs.
Groups Caspase-3
activity
Caspase-8
activity
Caspase-9
activity
mock HUVEC 0.063 ± 0.002 0.021 ± 0.003 0.035 ± 0.005
HUVEC/control-
shRNA
0.070 ± 0.004 0.038 ± 0.003 0.049 ± 0.003
HUVEC/ANXA2-
shRNA
0.112 ± 0.003a 0.061 ± 0.007a 0.053 ± 0.008a
a vs. mock HUVEC, P < 0.01.
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(P < 0.01 or P < 0.05) compared with that in the HUVEC/
control-shRNA cells and in the mock HUVECs. The result
indicated that the growth of HUVEC/ANXA2-shRNA cells was
markedly inhibited in vitro.
3.4. Silencing ANXA2 enhances apoptosis of HUVECs
Cells were analyzed using an FACS by the staining method
with FITC-conjugated annexin V and PI (Figure 4). The number
of HUVEC/ANXA2-shRNA cells undergoing apoptosis was
41.9% and increased by 102.61% compared to the mock
HUVECs (P < 0.01), which suggests that ANXA2 silencing
enhances apoptosis in HUVECs.Figure 5. Western blot analysis.
M, mock HUVEC; C, HUVEC/control-shRNA; A, HUVEC/ANXA2-shRNA.3.5. Silencing ANXA2 affects the levels of caspase-3, -8
and -9
Since the above results suggest that silencing of ANXA2
upregulates apoptosis, we intended to investigate the activity of
apoptosis-related caspases. The activity levels of HUVEC
caspase-3, -8 and -9 were estimated with the use of ELISA kits
(Table 2). The levels of caspase-3, -8 and -9 in HUVEC/
ANXA2-shRNA cells was 0.112, 0.061 and 0.053, respectively
compared with 0.063, 0.021 and 0.035 in the mock HUVECs
(P < 0.01). It suggests that ANXA2 silencing increased the
activity levels of HUVEC caspase-3, caspase-8 and caspase-9.
Furthermore, the total protein was isolated from cultured cells
and was analyzed by means of western blotting (Figure 5). The
cleaved caspase-3, cleaved caspase-8 and cleaved caspase-9
were upregulated by 56.29%, 89.59% and 144.58% compared
to that in mock HUVECs (P < 0.01).
4. Discussion
ANXA2 is a member of the annexin family of proteins and
exists either in monomeric form or as a heterotetramer con-
taining two light chains of S100A10/p11 and two chains of
ANXA2, which has recently drawn attention for its ability to
regulate multiple key processes in cells [21–23]. In the present
study, we focus on the effects of silencing ANXA2 by
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in vitro.
shRNA is a sequence of RNA that makes a tight hairpin turn
that can be used to silence target gene expression via RNA
interference (RNAi) [24,25]. Expression of shRNA in cells is
typically accomplished by delivery of plasmids or through
viral or bacterial vectors [26]. In this work, the shRNA
targeting ANXA2 was designed and cloned into double
marked lentivirial vector GV248 for RNAi to generate the
recombinant expression plasmids, which were infected into
HUVEC resulting in the stably transfected experimental
(ANXA2-shRNA) cell line, HUVEC/ANXA2-shRNA, with an
inhibition rate 91.89% of ANXA2 expression compared to the
mock and the control HUVECs.
Our data showed that ANXA2 silencing cell strain obviously
presented a lower cell proliferation activity compared to the
control and mock HUVECs. In addition, FACS analysis indi-
cated that the HUVEC/ANXA2-shRNA cells undergoing
apoptosis increased by 102.61% compared to the mock
HUVECs (P < 0.01), which is in agreement with previous
research. How ANXA2 affects cell apoptosis? Huang [27]
reported that ANXA2 was involved in P53-mediated apoptosis
in that ANXA2 levels decreased signiﬁcantly in P53 induced
cell apoptosis. Madureira et al [28–31] revealed that ANXA2
could protect DNA from degradation. These results suggested
that ANXA2 may affect the P53 expression and its activity,
and the down proteins such as Bcl2, Bax, and caspase family
to inhibit cell apoptosis. In this paper, we have also conﬁrmed
this viewpoint. The activated cleaved caspase-3, cleaved
caspase-8 and cleaved caspase-9 of the HUVEC/ANXA2-
shRNA cells were upregulated evidently compared with that
of the control and mock HUVECs by 56.29%, 89.59% and
144.58% (P < 0.01).
Collectively, the results revealed a link between the level of
ANXA2 expression and cell apoptosis, which suggested that the
potential utility of ANXA2 as a predictive biomarker for
detecting angiogenesis and that ANXA2 might be used in the
treatment of neovascularization disorders as a therapeutic target
of molecular-based strategies.
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